Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

The attrition rate for anticancer drugs entering clinical trials is unacceptably high. For multiple myeloma (MM), we postulate that this is because of preclinical models that overemphasize the antiproliferative activity of drugs, and clinical trials performed in refractory end-stage patients. We val...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chesi, Marta, Matthews, Geoffrey M., Garbitt, Victoria M., Palmer, Stephen E., Shortt, Jake, Lefebure, Marcus, Stewart, A. Keith, Johnstone, Ricky W., Bergsagel, P. Leif
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3398763/
https://ncbi.nlm.nih.gov/pubmed/22451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-412783
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars